Skip to main content
OpenTrials

Clinical trial condition

Carcinoma, Bronchogenic

Explore clinical trials studying Carcinoma, Bronchogenic. Study availability and eligibility vary by location and protocol.

5,226 public trials 1,176 recruiting studies
Refine in advanced search Browse all conditions

Carcinoma, Bronchogenic trial results

Recruiting

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

NCT07361497

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
Locations
  • Southern Cancer Center Pc Daphne, Alabama, United States
  • Local Institution - 0780 Chandler, Arizona, United States
  • Intermountain Health Cancer Center Lutheran Hospital Golden, Colorado, United States
  • Medical Oncology Hematology Consultants, PA Newark, Delaware, United States
View all 256 locations
View Trial Details
Recruiting

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

NCT07190248

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
Locations
  • Central Alabama Research ( Site 0108) Birmingham, Alabama, United States
  • University of Connecticut Health Center ( Site 0130) Farmington, Connecticut, United States
  • Stamford Hospital ( Site 0126) Stamford, Connecticut, United States
  • Mount Sinai Cancer Center ( Site 0137) Miami Beach, Florida, United States
View all 195 locations
View Trial Details
Recruiting

A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)

NCT07218146

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Lung Diseases, +8 more
Locations
  • Zai Lab Site 02050 La Jolla, California, United States
  • Zai Lab Site 02033 Sacramento, California, United States
  • Zai Lab Site 02037 Aurora, Colorado, United States
  • Zai Lab Site 02030 New Haven, Connecticut, United States
View all 76 locations
View Trial Details
Recruiting

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

NCT07361510

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
Locations
  • Southern Cancer Center Pc Daphne, Alabama, United States
  • Mohtaseb Cancer Center & Blood Disorders Bullhead City, Arizona, United States
  • Palo Verde Hematology Oncology Glendale, Arizona, United States
  • Local Institution - 0407 Anaheim, California, United States
View all 274 locations
View Trial Details
Recruiting

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

NCT06422143

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +9 more
Locations
  • CARTI Cancer Center ( Site 0006) Little Rock, Arkansas, United States
  • Roy and Patricia Disney Family Cancer Center - Providence Saint Joseph Medical Center ( Site 0122) Burbank, California, United States
  • Sharp Memorial Hospital ( Site 9544) San Diego, California, United States
  • Intermountain Health Cancer Center Lutheran Hospital ( Site 0119) Golden, Colorado, United States
View all 215 locations
View Trial Details
Recruiting

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

NCT06881784

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +12 more
Locations
  • Alabama Oncology Birmingham, Alabama, United States
  • MemorialCare Long Beach Medical Center Long Beach, California, United States
  • Yale University, Smillow Cancer Center New Haven, Connecticut, United States
  • Florida Cancer Specialists & Research Institute - South Fort Myers, Florida, United States
View all 152 locations
View Trial Details
Recruiting

A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer

NCT07325136

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Lung Diseases, +8 more
Locations
  • Karmanos Cancer Institute Detroit, Michigan, United States
  • Local Institution - 0026 Buffalo, New York, United States
  • Duke Cancer Institute Durham, North Carolina, United States
  • University Hospitals Cleveland Medical Center Cleveland, Ohio, United States
View Trial Details

Related conditions